Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Institute (NCI)
OBJECTIVES:
I. Measure the potential doubling times of multifocal adenocarcinomas of the prostate using broxuridine.
II. Determine whether the doubling times of multifocal carcinomas occurring within a single prostate are consistent with a model in which low-volume carcinomas have slow doubling times and high-volume carcinomas have fast doubling times.
OUTLINE:
Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate. Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
Age
Any age
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of stage I or II (T1-2) carcinoma of the prostate
* PSA greater than 8 ng/mL
* Abnormal findings on digital rectal examination
Eligible for radical prostatectomy
Performance status - ECOG 0 or 1
No prior biologic therapy
No prior chemotherapy
No prior neoadjuvant hormonal therapy
No prior radiotherapy
See Disease Characteristics
No prior therapy that would affect tumor growth rates or volume
Clareo Health | Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
